Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, has announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.
The move strategically places OBT at the centre of the rapidly growing Oxford biotech ecosystem, where it can benefit from the world class expertise and human capital that Oxford has to offer.
OBT joins other innovative biotech companies and research institutes to make this transition, including the recently announced Oxford expansion of the Ellison Institute for Transformative Medicine.
OBT’s new headquarters will allow it to leverage the local network of high-quality talent, which benefits from its close proximity to the University of Oxford.
Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “We are excited to be moving to The Oxford Science Park, to work alongside many of the UK’s leading biotech companies."
"The move marks another key milestone in our growth, fuelled by our proprietary OGAP discovery platform and excellent progress in our clinical and preclinical programmes with our pharmaceutical partners."
"Our new, enlarged and cutting-edge R&D space will allow us to build on our leading target discovery capabilities and accelerate our progress in developing novel immunotherapies to transform the lives of people living with cancer.”
